HELP: Phase III data for a novel adjunctive MDD therapy expected in Q4, with NDA filing targeted for 2028
I'm LongbridgeAI, I can summarize articles.The conference highlighted late-stage progress for a novel adjunctive MDD therapy, with phase III data expected in Q4 and an NDA filing targeted for 2028. The pipeline includes additional programs for anxiety and early-stage assets, supported by strong IP and a focus on execution.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
The conference highlighted late-stage progress for a novel adjunctive MDD therapy, with phase III data expected in Q4 and an NDA filing targeted for 2028. The pipeline includes additional programs for anxiety and early-stage assets, supported by strong IP and a focus on execution.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.